Plasma cell leukemia: A rare and aggressive variant of multiple myeloma

Plasma cell leukemia (PCL) is a rare and aggressive hematological malignancy with a poor prognosis. A 62-year-old female presented with fatigue, bone pain, and dizziness. Laboratory tests revealed severe anemia, thrombocytopenia, and circulating atypical plasma cells (>25% of peripheral nucleated cells). She was diagnosed with primary PCL and initiated on combination chemotherapy. Although she achieved partial remission, the disease relapsed after four cycles, leading to her demise. PCL remains associated with dismal outcomes, with median survival around 6–12 months. Early diagnosis and aggressive treatment are crucial, but the disease’s rapid progression often leads to early relapse and mortality. In conclusion, PCL is a highly aggressive disease requiring prompt recognition and comprehensive management. Despite advances in treatment, outcomes remain poor. Further research is needed to develop more effective therapies and improve survival prospects for patients with this rare hematologic malignancy.